DBRG vs HTGC

DBRG exhibits a significant disconnect between its market price ($15.60) and its fundamental value, with a Piotroski F-Score of 4/9 indicating only stable health and a Graham Number of $8.81. While the stock has seen strong 1-year price momentum (+86.3%), this is not supported by the underlying financials, which show negative revenue growth (-27.6%) and negative ROE/ROA. The valuation is extreme, evidenced by a Price/Sales ratio of 30.31 and a PEG ratio of 3.06, suggesting the stock is trading at a speculative premium far above its intrinsic value of $3.36.

HTGC presents a stark contrast between deep fundamental value and deteriorating financial health markers. While the Piotroski F-Score of 2/9 indicates weak operational health and the technical trend is bearish, the stock trades significantly below its Graham Number ($22.61) and Intrinsic Value ($54.58). Strong growth in revenue and earnings is offset by a concerning dividend payout ratio of 101.62%, suggesting the current yield is unsustainable. The valuation is highly attractive, but the deterministic health scores necessitate a cautious approach.